#Canada #Vancouver #Clinical Trials #Psilocybin #Optimi Health

Optimi Health Completes First Export of Psilocybin to the UK

In a groundbreaking development, Optimi Health Corp. has successfully completed its inaugural export of psilocybin to the United Kingdom. This shipment is a significant step towards the company's planned Phase 2 clinical trial. The export follows the authorization from Health Canada and the UK Home Office, affirming the compliance of Optimi’s practices with international regulations.

The shipment consists of both psilocybin biomass and 5mg capsules. These capsules feature the same formulation used in Australia to treat patients with treatment-resistant depression (TRD). The company is expected to announce details regarding its trial partner and the specific indications involved in due course.

Manufactured at Optimi's Good Manufacturing Practice (GMP) facility located in Princeton, British Columbia, the psilocybin products were created under strict quality controls. Utilizing a proprietary extraction method, Optimi cultivated the biomass and produced the capsules in-house, demonstrating their capability to deliver high-quality, regulated psychedelic solutions from a single licensed facility. This vertical integration allows Optimi to serve both commercial markets and clinical trial needs efficiently.

Dane Stevens, CEO and Co-Founder of Optimi, expressed enthusiasm for this milestone, stating, “This is our first shipment into the United Kingdom, and it is the same psilocybin we already supply to patients in Australia. We can serve a commercial market and a clinical trial from the same GMP facility, on our own license. That is a rare position, and one we have spent years building.”

The significance of this export is amplified by the growing interest in psychedelic therapies for mental health conditions globally. Optimi is committed to providing finished psilocybin and MDMA drug products to regulated markets, emphasizing both clinical research and patient access. Inquiries related to special access programs and clinical trial supplies can be directed to the company’s designated email contact.

About Optimi Health Corp.:
Optimi Health Corp. operates as a commercial-stage pharmaceutical company focusing on the manufacturing and distribution of GMP-grade psychedelic drug products aimed at mental health treatments. It is licensed by Health Canada and produces validated MDMA and botanical psilocybin products within its GMP-compliant facilities located in British Columbia.

The company’s commitment extends internationally, supplying both active pharmaceutical ingredients and finished dosage forms for clinical and therapeutic programs. Products are currently prescribed to patients in Australia under an authorized prescriber scheme and are also accessible in Canada through its Special Access Program.

For more information about Optimi Health and its offerings, please visit their official website at www.optimihealth.ca or optimi.net.

As advances in psychedelic research continue to evolve, companies like Optimi Health are at the forefront of providing effective solutions. This first export to the UK represents a promising future for integrating psychedelics into mental healthcare treatment frameworks, and many in the industry are watching closely as the clinical trial unfolds.